This mild course is in contrast to JMML driven by somatic mutations in PTPN11, which are reported in 35% of patients with non-syndromic, de novo JMML and require hematopoietic stem cell transplantation (HSCT) for the best chance of cure [14]. Here, PTPN11 is linked to juvenile myelomonocytic leukemia.